Minamestane (INN (former developmental code name FCE-24,928) is a steroidal aromatase inhibitor which was under development by Farmitalia-Carlo Erba as an antineoplastic agent in the mid-1990s but was never marketed.[1][2][3]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H23NO2 |
Molar mass | 297.398 g·mol−1 |
3D model (JSmol) | |
| |
|
Unlike other steroidal aromatase inhibitors such as formestane and exemestane, minamestane does not have androgenic properties.[2]
See also
editReferences
edit- ^ F.. Macdonald (1997). Dictionary of Pharmacological Agents. CRC Press. p. 1357. ISBN 978-0-412-46630-4. Retrieved 20 May 2012.
- ^ a b Di Salle E, Briatico G, Giudici D, et al. (June 1994). "Novel aromatase and 5 alpha-reductase inhibitors". The Journal of Steroid Biochemistry and Molecular Biology. 49 (4–6): 289–94. doi:10.1016/0960-0760(94)90270-4. PMID 8043491. S2CID 54350143.
- ^ Combs, Donald W (1995). "Review Oncologic, Endocrine & Metabolic: Recent developments in aromatase inhibitors". Expert Opinion on Therapeutic Patents. 5 (6): 529533. doi:10.1517/13543776.5.6.529. ISSN 1354-3776.